Risk factors for nephrotoxicity in patients receiving outpatient continuous infusions of vancomycin in an Australian tertiary hospital

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 3, 2014, Pages 805-808

  Norton, Katherine ^a,b   Ingram, Paul R ^a,c   Heath, Christopher H ^a,d   Manning, Laurens ^a,d  

^a ROYAL PERTH HOSPITAL   (Australia)

^b Swan District Hospital   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Angiotensin blockade; OPAT; Steady state concentrations

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFECTIVE AGENT; VANCOMYCIN;

ADVERSE EFFECTS; AGED; AMBULATORY CARE; AUSTRALIA; CHEMICALLY INDUCED; COHORT ANALYSIS; DRUG INTERACTION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; MIDDLE AGED; OUTPATIENT; PREVALENCE; PROCEDURES; RETROSPECTIVE STUDY; RISK FACTOR; TERTIARY CARE CENTER;

AGED; AMBULATORY CARE; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTI-BACTERIAL AGENTS; AUSTRALIA; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OUTPATIENTS; PREVALENCE; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; VANCOMYCIN;

EID: 84894100006     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt402     Document Type: Article

References (15)

1. Tice AD, Rehm SJ, Dalovisio JR et al. Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines. Clin Infect Dis 2004; 38: 1651-72.
2. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
3. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
4. Antibiotic Expert Group. Therapeutic Guidelines: Antibiotics. Version 14. Melbourne: Therapeutic Guidelines Limited, 2010.
5. James JK, Palmer SM, Levine DPet al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented Gram-positive infections. Antimicrob Agents Chemother 1996; 40: 696-700.
6. Bernard E, Perbost I, Carles M et al. Efficacy and safety of vancomycin constant-rate infusion in the treatment of chronic Gram-positive bone and joint infections. Clin Microbiol Infect 1997; 3: 440-6.
7. Bosso JA, Nappi J, Rudisill C et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother 2011; 55: 5475-9.
8. Ingram PR, Lye DC, Tambyah PA et al. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008; 62: 168-71.
9. Norton K, Ingram PR, Heath CH et al. Neutropenia is rare in patients receiving continuous infusions of vancomycin in an Australian Hospital in the Home setting. Intern Med J 2013; 43: 954-5.
10. Therneau T, Atkinson B. rpart: Recursive Partitioning. Version 3.1-48. R package, 2010.
11. Fisher DA, Kurup A, Lye D et al. Outpatient parenteral antibiotic therapy in Singapore. Int J Antimicrob Agents 2006; 28: 545-50.
12. Wong-Beringer A, Joo J, Tse E et al. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011; 37: 95-101.
13. Elyasi S, Khalili H, Dashti-Khavidaki S et al. Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. Eur J Clin Pharmacol 2012; 68: 1243-55.
14. Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42 Suppl 1: S35-9.
15. Leu WJ, Liu YC, Wang HW et al. Evaluation of a vancomycin dosing nomogram in achieving high target trough concentrations in Taiwanese patients. Int J Infect Dis 2012; 16: e804-10.